NJ Doctor Serge Menkin Loses DEA Registration Permanently
Published Date: 6/10/2025
Notice
Summary
Dr. Serge Menkin from New Jersey lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of January 31, 2025. This means Dr. Menkin can’t legally work with controlled drugs anymore, and the decision is final.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Menkin
The Drug Enforcement Administration revoked Serge Menkin, M.D.'s DEA Certificate of Registration No. BM8723795. The revocation is effective July 10, 2025, and follows findings that he is not authorized to handle controlled substances in New Jersey; his DEA registration had expired on January 31, 2025.
Pending and New New Jersey Registrations Denied
The Order denies any pending applications by Serge Menkin, M.D., to renew or modify his DEA registration and also denies any other pending application he has for additional registration in New Jersey. This denial is issued pursuant to the same Order effective July 10, 2025.
15-Day Reconsideration Right to Dispute Fact
The Order gives Serge Menkin, M.D., the right to file a properly supported motion for reconsideration of the Agency's factual finding that he lacks authority to handle controlled substances in New Jersey. Any such motion must be filed within fifteen calendar days of the date of the Order and served by email to the DEA Office of the Administrator at [email protected].
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-10501 — Harry Kram, M.D.; Decision and Order
Dr. Harry Kram from California lost his DEA registration because he no longer has permission to handle controlled substances in his state. Despite being notified, he didn’t ask for a hearing, so the DEA officially revoked his registration by default. This means Dr. Kram can’t legally prescribe or handle controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Next: 2025-10504 — Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to the Alaska Department of Transportation and Public Facilities Angoon Ferry Terminal Modification Project in Angoon, Alaska
The Alaska Department of Transportation is updating the Angoon Ferry Terminal in Alaska, and this work might accidentally bother some marine mammals nearby. They've got permission to do this safely without hurting the animals, following important rules. The project will happen soon and aims to improve ferry services while protecting wildlife.